ENDP - Endo International plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.00
-0.07 (-1.15%)
At close: 4:00PM EST

5.83 -0.17 (-2.83%)
After hours: 4:43PM EST

Stock chart is not supported by your current browser
Previous Close6.07
Open5.98
Bid6.03 x 40000
Ask6.04 x 3100
Day's Range5.54 - 6.43
52 Week Range1.97 - 12.49
Volume13,632,613
Avg. Volume6,680,640
Market Cap1.361B
Beta (5Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)-2.20
Earnings DateFeb 25, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.47
  • Endo International chooses a familiar face to be new CEO
    American City Business Journals

    Endo International chooses a familiar face to be new CEO

    Endo International has found its new president and chief executive officer in-house. The Dublin, Ireland-based pharmaceutical company, which has its U.S. headquarters in Malvern, said Blaise Coleman will take over as CEO effective March 6. Coleman has served as executive vice president and chief financial officer at Endo (NASDAQ: ENDP) since 2016.

  • Endo Names Blaise Coleman President and Chief Executive Officer
    CNW Group

    Endo Names Blaise Coleman President and Chief Executive Officer

    DUBLIN , Feb. 19, 2020 /CNW/ -- Endo International plc (ENDP) today announced that Blaise Coleman , who has served as the Company's Executive Vice President and Chief Financial Officer since 2016, will succeed Paul Campanelli as President and Chief Executive Officer and will become a member of the Board of Directors effective March 6, 2020 . Mr. Campanelli will continue to serve as Chairman of the Board. This appointment will complete the Chief Executive Officer succession plan that Endo announced in November 2019 .

  • Endo Appoints Mark G. Barberio to Board of Directors
    CNW Group

    Endo Appoints Mark G. Barberio to Board of Directors

    Endo Appoints Mark G. Barberio to Board of Directors

  • Earnings Preview: Endo International (ENDP) Q4 Earnings Expected to Decline
    Zacks

    Earnings Preview: Endo International (ENDP) Q4 Earnings Expected to Decline

    Endo (ENDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Small-Cap Healthcare ETF Outperforming in 2020: 5 Top Stocks
    Zacks

    Small-Cap Healthcare ETF Outperforming in 2020: 5 Top Stocks

    The small-cap healthcare companies are benefiting from the 2020 presidential election campaign, which has put pressure on the large cap cousins on how to overhaul the industry.

  • Here's Why You Should Add BioDelivery Stock to Your Portfolio
    Zacks

    Here's Why You Should Add BioDelivery Stock to Your Portfolio

    Here are five reasons which make BioDelivery (BDSI)) a good investment option in 2020.

  • CNW Group

    Endo Begins Shipment of Authorized Generic Version of Carafate® (sucralfate) Oral Suspension in the United States

    Endo Begins Shipment of Authorized Generic Version of Carafate® (sucralfate) Oral Suspension in the United States

  • CNW Group

    Endo to Announce Fourth-Quarter and Full-Year 2019 Financial Results

    Endo to Announce Fourth-Quarter and Full-Year 2019 Financial Results

  • J&J's $8B Jury Award in Risperdal Case Cut to $6.8M by Judge
    Zacks

    J&J's $8B Jury Award in Risperdal Case Cut to $6.8M by Judge

    A Philadelphia judge slashes J&J's (JNJ) punitive damages in a lawsuit, which claims that the company did not warm men that they could grow breasts by using its antipsychotic drug, Risperdal.

  • Endo reaches $8.75M opioid settlement with Oklahoma
    American City Business Journals

    Endo reaches $8.75M opioid settlement with Oklahoma

    Two Endo International Inc. subsidiaries have agreed to pay Oklahoma $8.75 million to resolve the state’s investigation into whether the pharmaceutical company had a role in the state’s opioid abuse crisis. The settlement agreement, under which the Endo business units admitted to no wrongdoing or liability, involved Endo Pharmaceuticals Inc. and Par Pharmaceuticals. Endo officials noted the amount it agreed to pay in connection with the settlement agreement is a "fraction" of the settlement and judgment amounts associated with other opioid manufacturers in Oklahoma.

  • Endo Up on Opioid Abuse Settlement Agreement With Oklahoma
    Zacks

    Endo Up on Opioid Abuse Settlement Agreement With Oklahoma

    Endo (ENDP) settles an ongoing opioid-abuse litigation issue with the state of Oklahoma for $8.75 million.

  • MarketWatch

    Endo settles opioid suit with Oklahoma AG

    Shares of Endo International Inc. are up 3% in afternoon trading on Friday after the company said it will pay $8.75 million to Oklahoma to settle allegations that it inappropriately promoted its opioids. As part of the settlement, the company did not admit wrongdoing. According to a news release from the Attorney General's office, Endo will not employ or contract with sales reps in Oklahoma and will not pay for direct or indirect promotion of opioids. Endo has also settled similar opioid-related lawsuits with two counties in Ohio. Endo's stock has tumbled 52% over the last year. The Health Care Select Sector SPDR exchange-traded fund is up 17%.

  • PR Newswire

    Endo Settles Opioid Investigation with State of Oklahoma for $8.75 million

    Endo International plc (NASDAQ: ENDP) today announced that its subsidiaries Endo Pharmaceuticals Inc. and Par Pharmaceutical, Inc. (collectively, the "Settling Parties") have executed a Settlement Agreement with the State of Oklahoma ("Oklahoma"). The Settlement Agreement fully and finally resolves Oklahoma's investigation of the Settling Parties in connection with the opioid abuse crisis in Oklahoma and includes a release of all associated claims by Oklahoma to the Settling Parties and all of their affiliated entities and persons (collectively, the "Endo Affiliates"). In connection with the Settlement Agreement, Endo Pharmaceuticals Inc. has agreed to pay $8.75 million to Oklahoma. The Settlement Agreement includes no admission of wrongdoing, fault or liability of any kind by the Endo Affiliates. The amount paid in connection with the Settlement Agreement is a fraction of the settlement and judgment amounts associated with other opioid manufacturers in Oklahoma to date and is the result of direct engagement among Oklahoma Attorney General Mike Hunter, his staff and counsel, and the Company's senior leadership.

  • Will J&J be Able to Overcome Its Legal Troubles in 2020?
    Zacks

    Will J&J be Able to Overcome Its Legal Troubles in 2020?

    Here we discuss the growth potential of J&J's (JNJ) stock in 2020.

  • Implied Volatility Surging for Endo (ENDP) Stock Options
    Zacks

    Implied Volatility Surging for Endo (ENDP) Stock Options

    Investors need to pay close attention to Endo (ENDP) stock based on the movements in the options market lately.

  • PR Newswire

    Endo to Participate at J.P. Morgan Healthcare Conference

    Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 13, 2020 at 3:30 p.m. PST.

  • CNW Group

    Endo Launches Generic Version of Afinitor® (everolimus) Tablets in the United States

    Endo Launches Generic Version of Afinitor® (everolimus) Tablets in the United States

  • Did Hedge Funds Drop The Ball On Endo International plc (ENDP) ?
    Insider Monkey

    Did Hedge Funds Drop The Ball On Endo International plc (ENDP) ?

    It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]